Short Communication

Does type 2 diabetes influence the risk of oesophageal adenocarcinoma?

RE Neale*,1, JD Doecke¹, N Pandeya¹,2, S Sadhegi², AC Green¹, PM Webb¹ and DC Whiteman¹ for The Australian Cancer Study²

¹Cancer and Population Studies Group, Queensland Institute of Medical Research, Queensland, Australia; ²School of Population Health, University of Queensland, Brisbane, Queensland, Australia

Since hyperinsulinaemia may promote obesity-linked cancers, we compared type 2 diabetes prevalence among oesophageal adenocarcinoma (OAC) patients and population controls. Diabetes increased the risk of OAC (adjusted odds ratio 1.59, 95% confidence interval (CI) 1.04–2.43), although the risk was attenuated after further adjusting for body mass index (1.32, 95% CI 0.85–2.05). British Journal of Cancer (2009) 100, 795–798. doi:10.1038/sj.bjc.6604908 www.bjcancer.com

Published online 3 February 2009
© 2009 Cancer Research UK

Keywords: oesophageal neoplasms; diabetes mellitus; case–control study

Adenocarcinomas of the oesophagus (OAC) and gastro-oesophageal junction (GOJAC) have been rising rapidly in incidence in many countries (Blot et al, 1991; Wayman et al, 2001; Pohl and Welch, 2005), widely attributed to the steadily rising prevalence of obesity (Silventoinen et al, 2004; Reeves et al, 2007; Whiteman et al, 2007; Corley et al, 2008).

One proposed mechanism to explain the association between obesity and OAC is that obesity increases the risk of OAC through the pathway of gastro-oesophageal acid reflux. However, we and others have shown that obesity is strongly associated with OAC (Corley et al, 2008) even among people with no history of reflux (Chow et al, 1998; Whiteman et al, 2007), arguing against increased exposure to acid as being the sole mechanism for the observed phenomenon. A second postulated mechanism is that the metabolic changes accompanying adiposity establish a hormonal milieu that promotes the development of nascent tumours (Calle and Kaaks, 2004).

A candidate hormone central to the ‘metabolic hormonal hypothesis’ is insulin. Insulin activates the insulin receptor, triggering intracellular signalling cascades with mitogenic and antiapoptotic effects (Calle and Kaaks, 2004). In addition, its positive feedback influences levels of leptin, a mitogenic adipokine that has been implicated in cancers of the colon, breast and prostate (Tessitore et al, 2000; Stattin et al, 2003). If hyperinsulinaemia is positively associated with the risk of OAC, then an association with type 2 diabetes (a proxy for pre-existing hyperinsulinaemia) should be observed, independently of other obesity-related factors.

Although some studies investigated oesophageal cancer in relation to diabetes, only three distinguished adenocarcinomas from squamous cell carcinomas (Cheng et al, 2000; Reavis et al, 2004; Rubenstein et al, 2005). For each study, however, the prevalence of diabetes among controls was markedly different from prevailing population estimates. We therefore used data from a large population-based case–control study to explore the hypothesis and address some gaps in the evidence.

METHODS

The study was approved by the human research ethics committees of the Queensland Institute of Medical Research and participating hospitals and we obtained written informed consent from all participants. Details of recruitment and data collection have been reported earlier (Whiteman et al, 2007). Briefly, patients (cases) with a primary invasive OAC or oesophageal squamous cell carcinoma (OSC) or diagnosed between 1 July 2001 and 30 June 2005 were recruited through major treatment centres and state-based cancer registries throughout mainland Australia. In all, 1102 patients returned questionnaires (75% of those meeting the inclusion criteria and invited to take part: 367 OAC, 426 GOJAC and 309 OSC).

Potential controls were randomly selected from the Australian electoral roll (enrolment is compulsory), matched to the distribution of the case-series by age, sex and state of residence. Completed questionnaires were returned by 1580 controls (52% of all controls meeting the inclusion criteria).

Data were collected through self-completed questionnaires about education, occupation, smoking, medication use, maximum weight and height and weight 1 year ago. We calculated BMI by dividing weight in kilograms by the square of height in metres. Participants were asked about the frequency of symptoms of gastro-oesophageal reflux. For analysis, we defined ‘frequent symptoms’ as those occurring at least weekly.

Diabetes was self-reported using the questions ‘Have you ever had diabetes treated with insulin injections?’ and ‘Have you ever had diabetes treated with tablets and/or diet?’ A positive response to either of these questions prompted a question about the age of diagnosis. We classified those who reported diabetes treated only
Type 2 diabetes and the risk of oesophageal adenocarcinoma?
RE Neale et al

with tablets/diet as having type 2 diabetes. Participants who had insulin-treated diabetes were considered to have type 2 diabetes if they were diagnosed after the age of 25 years.

Details of the histological type and anatomical site of each tumour were abstracted from diagnostic pathology reports. Tumours were categorised according to the WHO classification as ‘oesophageal’ or of the ‘gastro-oesophageal junction’ (Spechler et al., 2000). We calculated the odds ratios (ORs) and 95% confidence intervals (95% CIs) associated with diabetes using multivariable logistic regression analysis in SAS version 9.1 (SAS Institute Inc., Cary, NC). We first fitted models that contained terms for diabetes, age and sex (Model 1). We then estimated risks associated with diabetes adjusted for these variables and education, smoking, frequency of aspirin use and frequency of gastro-oesophageal reflux symptoms (Model 2). Finally, we fitted models comprising the preceding variables as well as BMI (Model 3).

RESULTS

The demographic and clinical characteristics of cases and controls have been reported earlier (Sadeghi et al., 2008). Diabetes was self-reported by 7% of controls, compared with 14, 12 and 4% of cases who had OAC, GOJAC and OSCC, respectively.

In simple models adjusted only for age and sex, we found a significant increase in the risk of OAC associated with diabetes (Model 1: OR 1.78, 95% CI 1.22 – 2.62) that was somewhat attenuated by adjustment for additional factors (Table 1). Adding the term for BMI to the model further attenuated the estimate, with the final OR suggesting a 32% increase in risk of OAC associated with diabetes, although this increase was no longer statistically significant (Model 3: OR 1.32, 95% CI 0.85 – 2.05). Similar patterns with diabetes, although this increase was no longer statistically significant (Model 3: OR 1.32, 95% CI 0.85 – 2.05). Similar patterns with diabetes, although this increase was no longer statistically significant (Model 3: OR 1.32, 95% CI 0.85 – 2.05). Similar patterns with diabetes, although this increase was no longer statistically significant (Model 3: OR 1.32, 95% CI 0.85 – 2.05).

Diabetes duration

We observed consistently higher risks of OAC among those with diabetes within each category of BMI. People with diabetes who were also obese were at a 3.5-fold higher risk of OAC than those with neither risk factor (OR 3.55, 95% CI 1.87 – 6.76). Oesophageal adenocarcinoma risks were somewhat lower in those with either obesity or diabetes alone (obese OR 2.67, 95% CI 1.80 – 3.96; diabetes OR 1.86, 95% CI 0.65 – 5.31). In contrast to OAC, the odds of OSCC were significantly lower in people with diabetes compared with those without (OR 0.54, 95% CI 0.29 – 1.0) (Table 1).

DISCUSSION

Obesity is an established risk factor for OAC, although the precise mechanism involved remains unknown. An emerging hypothesis is that metabolic aberrations accompanying obesity lead to changes in hormones and cytokines, including insulin. We indirectly tested this ‘metabolic hormonal hypothesis’ by comparing the diabetes prevalence among oesophageal cancer patients with population controls, and found that those with adenocarcinoma were more likely than controls to report a history of diabetes. The association was greater for long-standing diabetes than for more recent diagnoses. In contrast, we found the suggestion of an inverse association between diabetes and OSCC.

The risk estimates generated by different multivariable models warrant comment. As excess body fat leads to high levels of insulin (and eventually to diabetes) and as diabetes is a proxy measure for hyperinsulinaemia, the inclusion of terms for both of these factors in the same model may underestimate the real effect of hyperinsulinaemia. One could argue that the effect of hyperinsulinaemia is best estimated by Model 2, which adjusts the association between diabetes and OAC for factors that might explain the confounding effect of BMI (e.g., gastro-oesophageal reflux symptoms 10 years before diagnosis and frequency of aspirin use in the last 5 years).  

Table 1  Relative risks for adenocarcinomas of the oesophagus (OAC), gastro-oesophageal junction (GOJAC) and squamous cell carcinoma (OSCC) associated with type 2 diabetes; minimally, partially and fully adjusted for confounding factors

| History of type 2 diabetes | Control (N) | Case (N) | OR (95% CI)a | OR (95% CI)b | OR (95% CI)c |
|---------------------------|------------|----------|---------------|---------------|---------------|
| OAC                       |            |          |               |               |               |
| No diabetes               | 1423       | 293      | 1.0 (ref)     | 1.0 (ref)     | 1.0 (ref)     |
| Diabetes                  | 103        | 46       | 1.78 (1.22 – 2.62) | 1.59 (1.04 – 2.43) | 1.32 (0.85 – 2.05) |
| No diabetes               | 1423       | 293      | 1.0 (ref)     | 1.0 (ref)     | 1.0 (ref)     |
| Diabetes duration < 10 years | 68        | 25       | 1.46 (0.90 – 2.38) | 1.39 (0.82 – 2.36) | 1.14 (0.66 – 1.97) |
| Diabetes duration ≥ 10 years | 30        | 18       | 2.45 (1.32 – 4.57) | 1.96 (0.97 – 3.97) | 1.65 (0.80 – 3.40) |
| P-trend                   |            |          |               |               | 0.18          |
| GOJAC                     |            |          |               |               |               |
| No diabetes               | 1423       | 338      | 1.0 (ref)     | 1.0 (ref)     | 1.0 (ref)     |
| Diabetes                  | 103        | 44       | 1.56 (1.06 – 2.28) | 1.44 (0.96 – 2.16) | 1.23 (0.82 – 1.87) |
| No diabetes               | 1423       | 338      | 1.0 (ref)     | 1.0 (ref)     | 1.0 (ref)     |
| Diabetes (duration < 10 years) | 68        | 20       | 1.06 (0.63 – 1.79) | 0.90 (0.57 – 1.71) | 0.87 (0.50 – 1.51) |
| Diabetes (duration ≥ 10 years) | 30        | 22       | 2.76 (1.55 – 4.91) | 2.46 (1.33 – 4.55) | 2.16 (1.16 – 4.04) |
| P-trend                   |            |          |               |               | 0.07          |
| OSCC                      |            |          |               |               |               |
| No diabetes               | 1423       | 270      | 1.0 (ref)     | 1.0 (ref)     | 1.0 (ref)     |
| Diabetes                  | 103        | 12       | 0.54 (0.29 – 1.0) | 0.48 (0.25 – 0.91) | 0.57 (0.30 – 1.10) |
| No diabetes               | 1423       | 270      | 1.0 (ref)     | 1.0 (ref)     | 1.0 (ref)     |
| Diabetes (duration < 10 years) | 68        | 7        | 0.49 (0.22 – 1.08) | 0.42 (0.18 – 0.97) | 0.52 (0.23 – 1.20) |
| Diabetes (duration ≥ 10 years) | 30        | 5        | 0.73 (0.28 – 1.92) | 0.62 (0.23 – 1.67) | 0.70 (0.25 – 1.93) |
| P-trend                   |            |          |               |               | 0.17          |

CI = confidence interval; OR = odds ratio. aOR: Model 1: adjusted for age (in years) and sex. bOR: Model 2: adjusted for age (in years), education level, cumulative smoking history, frequency of gastro-oesophageal reflux symptoms 10 years before diagnosis and frequency of aspirin use in the last 5 years. cOR: Model 3: as for Model 2 with an additional term for BMI.
REFERENCES

Blot WJ, Devesa SS, Kneller RW, Fraumeni Jr JF (1991) Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 265: 1287–1289

Calle EE, Kaaks R (2004) Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer 4: 579–591

Cheng KK, Sharp L, Gammon MD, Stanford JL, Dubrow R, Schoenberg JB, Mayne ST, Farrow DC, Ahsan H, West AB, Rotterdam H, Niwa S, Fraumeni Jr JF (1998) Body mass index and risk of adenocarcinomas of the esophagus and gastric cardia. J Natl Cancer Inst 90: 150–155

Corley DA, Kubo A, Zhao W (2008) Abdominal obesity and the risk of esophageal and gastric cardia carcinomas. Cancer Epidemiol Biomarkers Prev 17: 352–358

Dunstan DW, Zimmet PZ, Welborn TA, Sicree R, Armstrong T, Atkins R, Cameron A, Shaw J, Chadban S, Committee AS (2001) Diabesity and Associated Disorders in Australia – 2000. The Accelerating Epidemic International Diabetes Institute: Melbourne

Pohl H, Welch HG (2005) The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst 97: 142–146

Reavis KM, Morris CD, Gopal DV, Hunter JG, Jobe BA (2004) Laryngopharyngeal reflux symptoms better predict the presence of esophageal adenocarcinoma than typical gastrointestinal reflux symptoms. Ann Surg 239: 849–856; discussion 856–8

Reeves GK, Pirie K, Eral V, Green J, Spencer E, Bull D (2007) Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort study. BMJ 335: 1134

Appendix

The Australian Cancer Study: Oesophageal Cancer Contributors

Investigators: David C Whiteman MBBS, PhD, Penelope M Webb MA, D Phil, Adele C Green MBBS, PhD, Nicholas K Hayward PhD, Peter G Parsons PhD and David M Purdie PhD.

Clinical collaborators: B Mark Smithers FRACS, David Gotley FRACS PhD, Andrew Clouston FRACP PhD and Ian Brown FRACP.

Project manager: Suzanne Moore RN, MPH.

Research nurses: Suzanne O’Brien RN MPH, Ellen Minehan RN, Deborah Roife RN, Sue O’Keefe RN, Suzanne Lipshut RN, Gabby Rothman KJ (2002) Epidemiology: An Introduction. Oxford University Press: New York

Rubenstein JH, Davis J, Marrero JA, Inadomi JM (2005) Relationship between diabetes mellitus and adenocarcinoma of the oesophagus and gastric cardia. Aliment Pharmacol Ther 22: 267–271

Sagedhi S, Rain CJ, Pandeya N, Webb PM, Green AG, Whiteman DC (2008) Aspirin, nonsteroidal anti-inflammatory drugs, and the risks of cancers of the esophagus. Cancer Epidemiol Biomarkers Prev 17: 1169–1178

Spechler S, Dixon M, Genta R (2000) Adenocarcinoma of the oesophago-gastric junction. In Pathology and Genetics of Tumours of the Digestive System. WHO Classification of Tumours, SR H, LA A (eds) Vol. 2 IARC Press: Lyon

Stattin P, Palmqvist R, Soderberg S, Biessy C, Arndor B, Hallmans G, Kaaks R, Olsson T (2003) Plasma leptin and colorectal cancer risk: a prospective study in Northern Sweden. Oncol Rep 10: 2015–2021

Tessitore L, Vizio B, Jenkins O, De Stefano I, Ritossa C, Argiles JM, Benedetto C, Mussa A (2000) Leptin expression in colorectal and breast cancer patients. Int J Mol Med 5: 421–426

Wayman J, Forman D, Griffin SM (2001) Monitoring the changing pattern of esophago-gastric cancer: data from a UK regional cancer registry. Cancer Causes Control 12: 943–949

Whiteman DC, Sagedhi S, Pandeya N, Smithers BM, Gotley DC, Bain CJ, Webb PM, Green AG (2007) Combined effects of obesity, acid reflux and smoking on the risk of adenocarcinomas of the oesophagus. Gut 57: 173–180

In summary, our data support the hypothesis that diabetes is associated with an increased risk of OAC and that this is unlikely to be due entirely to other factors associated with a high BMI. Resolution of this question requires a further analysis of existing or new population-based data sets, in which histological subtypes are treated as separate entities.

ACKNOWLEDGEMENTS

We thank Harish Babu, MD, for his assistance with pathology abstractions. This study was supported by the Cancer Council Queensland and the National Health and Medical Research Council (NHMRC) of Australia (program no. 199660). Rachel Neale, Penelope Webb and David Whiteman are supported by Research Fellowships from the National Health and Medical Research Council of Australia. The funding bodies played no role in the design or conduct of the study; the collection, management, analysis or interpretation of the data; or preparation, review or approval of the paper.
Garrett Smith FRACS, Ross Smith FRACS and David Storey FRACS.

Queensland: John Avramovic FRACS, John CrEse FRACP, Justin D’Arcy FRACS, Stephen Fairley FRACP, John Hansen FRACS, John Masson FRACP, Les Nathanson FRACS, Barry O’Loughlin FRACS, Leigh Rutherford FRACS, Richard Turner FRACS, Morgan Windsor FRACS South Australia: Justin Bessell FRACS, Peter Devitt FRACS, Glyn Jamieson FRACS and David Watson FRACS.

Victoria: Stephen Blamey FRACS, Alex Boussioutas FRACP, Richard Cade FRACS, Gary Crosthwaite FRACS, Ian Faragher FRACS, John Gribbin FRACS, Geoff Hebbard FRACP, George Kiroff FRACS, Bruce Mann FRACS, Bob Millar FRACS, Paul O’Brien FRACS, Robert Thomas FRACS and Simon Wood FRACS.

Western Australia: Steve Archer FRACS, Kingsley Faulkner FRACS and Jeff Hamdorf FRACS.